While the Flatiron database doesnot capture tumor genomic profiling given biomarker testing outside HER2 forfirst-line therapy remains experimental, certain oncogene amplifications such asMET and FGFR2 have been identified in aminority of gastroesophageal cancers and portend poor prognosis.15, -17 Such patients with poor prognostic biomarkers are likely underrepresented inrandomized second-line trials, but were not excluded in this analysis, as the onlytumor biomarker reported in the data set is HER2 status. Here, ERBB2 is linked to neoplasm.